Abstract
Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction.
Anticoagulation during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has traditionally been supported by anticoagulant unfractionated heparin (UFH). Recently, alternative anticoagulants such as low molecular weight heparin (LMWH) were included in the management of STEMI.
The aim of the present review is to compare efficacy and safety outcomes among patients receiving low molecular weight heparins (LMWH) or unfractionated heparin (UFH) while undergoing PCI for STEMI.
Keywords: STEMI, PCI, low-molecular weight heparins, unfractionated heparin, acute coronary syndromes, thrombosis, in – stent restenosis, bleeding, coronary intervention, adjuvant therapy.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention
Volume: 11 Issue: 2
Author(s): Chiara Cavallino, Matteo Santagostino, Emanuela Facchini, Virginia Di Ruocco and Andrea Rognoni
Affiliation:
Keywords: STEMI, PCI, low-molecular weight heparins, unfractionated heparin, acute coronary syndromes, thrombosis, in – stent restenosis, bleeding, coronary intervention, adjuvant therapy.
Abstract: Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction.
Anticoagulation during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has traditionally been supported by anticoagulant unfractionated heparin (UFH). Recently, alternative anticoagulants such as low molecular weight heparin (LMWH) were included in the management of STEMI.
The aim of the present review is to compare efficacy and safety outcomes among patients receiving low molecular weight heparins (LMWH) or unfractionated heparin (UFH) while undergoing PCI for STEMI.
Export Options
About this article
Cite this article as:
Cavallino Chiara, Santagostino Matteo, Facchini Emanuela, Ruocco Virginia Di and Rognoni Andrea, Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020004
DOI https://dx.doi.org/10.2174/1871525711311020004 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy
Current Cardiology Reviews Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice
Current Gene Therapy Synergistic Effect of L-Carnosine and EGCG in the Prevention of Physiological Brain Aging
Current Pharmaceutical Design Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Acid-Sensing Ion Channels: A Novel Therapeutic Target for Pain and Anxiety
Current Pharmaceutical Design Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Current Drug Delivery Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry Therapeutic Hypothermia for Cardiopulmonary Resuscitation: Why, When and How
Current Cardiology Reviews Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Current Medicinal Chemistry Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research